Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Shield Therapeutics has initiated randomised, double-blind and placebo controlled AEGIS 1 and AEGIS 2 Phase 3 clinical studies to assess the efficacy of ST10 as a twice-daily treatment for iron deficiency anaemia (IDA).
Subscribe to our email newsletter
ST10 is an oral ferric iron-based pharmaceutical that can be administered to patients with improved tolerability compared to currently marketed oral iron treatments, the company said.
The trial will be carried out in subjects with Ulcerative Colitis (UC) or Crohns disease who failed to respond to oral ferrous preparations.
Each study enrolling 120 patients, will measure the change in haemoglobin concentration from baseline to week 12.
The company expects to release the data of the trials in late 2012.